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Abstract
Activating HIV-1 proviruses in latent reservoirs combined with inhibiting viral spread might be an effective anti-HIV
therapeutic strategy. Active specific delivery of therapeutic drugs into cells harboring latent HIV, without the use of
viral vectors, is a critical challenge to this objective. In this study, nanoparticles of poly(lactic-co-glycolic acid)-
polyethylene glycol diblock copolymers conjugated with anti-CD45RO antibody and loaded with the histone
deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) and/or protease inhibitor nelfinavir (Nel) were tested
for activity against latent virus in vitro. Nanoparticles loaded with SAHA, Nel, and SAHA + Nel were characterized in
terms of size, surface morphology, zeta potential, entrapment efficiency, drug release, and toxicity to ACH-2 cells.
We show that SAHA- and SAHA + Nel-loaded nanoparticles can target latently infected CD4+ T-cells and stimulate
virus production. Moreover, nanoparticles loaded with SAHA + NEL were capable of both activating latent virus and
inhibiting viral spread. Taken together, these data demonstrate the potential of this novel reagent for targeting and
eliminating latent HIV reservoirs.
Keywords: HIV-1; CD45RO; Memory T cells; Nanoparticles
Background
HIV infection is associated with a very high viral load in
the body leading to a progressive depletion of immune
cells, particularly CD4+ T cells [1, 2]. The infection
can be treated with highly active antiretroviral therapy
(HAART) consisting of at least three drugs from at
least two classes of antiretroviral agents [3]. However,
HAART cannot eliminate latent HIV reservoirs in
resting CD4
+/CD45RO
+ T memory (Tm) cells [3, 4, 6].
The best way to completely eliminate this reservoir is
to reactivate latent HIV-1 by inducing proviral gene
expression [5]. Gene expression is controlled partly by
the coiling and uncoiling of DNA around histones.
This is accomplished with the assistance of histone
acetyl transferases (HAT), which acetylate the lysine
residues in core histone, resulting in less compact
and more transcriptionally active chromatin [7, 8].
Gene expression from the HIV long terminal repeat
can be modulated in this way to regulate latency. The
histone deacetylase (HDAC) [9, 10] removes acetyl
groups from lysine residues leading to the formation
of condensed chromatin via a strong association be-
tween histones and the long terminal repeat of HIV,
which obstructs the access of transcription factors
and represses gene expression [9, 10].
HDAC inhibitors (HDACi) such as vorinostat, also
known as suberoylanilide hydroxamic acid (SAHA),
flush HIV out from reservoirs of latently infected cells
by activating gene expression in proviruses [11, 12].
Concurrent treatment with an antiretroviral such as the
protease inhibitor nelfinavir (Nel) and an HDACi
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simultaneously activates latent viruses and inhibits their
spread. This treatment could produce a synergistic effect
resulting in the elimination of latent HIV reservoirs [13,
14]. Efficient drug delivery by polymer-drug conjugates
is a rapidly growing field. Advantages of the conjugates
over treatment with drugs alone, demonstrated by
clinical trials, include fewer side effects, enhanced thera-
peutic efficacy, and improved patient compliance. One
of the most effective materials for this purpose is poly
(lactic-co-glycolic acid)-polyethylene glycol (PLGA-
PEG), a biodegradable polymer [15, 16]. Nanoparticles
(NPs) of PLGA-PEG are formed by spontaneous associ-
ation with amphiphilic surfactants in aqueous medium
to form core (hydrophobic)-shell (hydrophilic) struc-
tures. Drugs can be loaded inside PLGA-PEG NPs
regardless of their hydrophobicity, and sustained release
of the drug can be maintained [15, 16]. However, the
NPs’ limited targeting ability leads to the release of the
loaded drug before reaching the site of action. Targeting
can be facilitated by modification with a variety of
functional molecules, including chemical compounds
or antibodies, via carboxyl and or amine groups on
the NP surface.
HIV mainly hides in “reservoirs” of CD4+ Tm cells
[17, 18] which express the cell-specific surface antigen
CD45RO. Specific binding to CD45RO through the
single-chain variable fragment (scFv) CD45RO antibody
can be used for targeted delivery of active drugs to
human Tm cells [17–19], resulting in reduced toxicity
and increased therapeutic effects of systemically deliv-
ered drugs. We designed a novel anti-HIV drug to
specifically deliver SAHA and Nel to human Tm cells
using scFv CD45RO-modified SAHA/Nel-loaded PLGA-
PEG NPs (scFvCD45RO-SAHA/Nel-NPs). In this study,
we used ACH-2 cells (HIV-1 latently infected cell lines)
to determine the efficiency of activation of latent virus





stannous octoate [Sn (Oct) 2: stannous 2-ethylhexanoate],
N-hydroxysuccinimide (NHS), dicyclohexylcarbodiimde
(DCC), and dimethyl sulfoxide (DMSO) were obtained
from Sigma-Aldrich (St. Louis, MO, USA). All the other
chemicals and reagents used were of analytical purity
grade or higher. RPMI 1640 medium was obtained from
Gibco Invitrogen (Carlsbad, CA, USA). Polyvinyl alcohol
205 (PVA 205; 88 % degree of hydrolyzation) was
purchased from Kuraray Co., Ltd., China. 4′,6′-Diami-
dino-2-phenylindole (DAPI) was purchased from Molecu-
lar Probes (Eugene, OR, USA). The PLGA (Mw = 8.0 kDa;
lactic acid: glycolic acid = 50:50) and PEG copolymer were
purchased from Boehringer Ingelheim (Ingelheim am
Rhein, Germany). Dimethylformamide (DMF) and aceto-
nitrile are from Sigma-Aldrich. Human T lymphocyte
(H9) and T lymphocytoid (ACH-2) cell lines, carrying one
or two copies of integrated HIV-1 proviruses, were from
the Experimental Animal Center (Wuhan University/
ABSL-3 Laboratory, Wuhan, China).
Cell Culture and HIV-1 Activation
H9 and ACH-2 cells were cultured in RPMI 1640
medium supplemented by 8–10 % fetal calf serum
(HyClone). Activation of latent HIV-1 was evaluated
with assays for HIV-1 RNA and p24 production. The
amount of p24 was measured by use of HIV-1 p24
ELISA (Abnova, Walnut, CA, USA).
Synthesis of PLGA-PEG Copolymer
PLGA-PEG diblock copolymers were synthesized by
conjugating NH2-PEG-OH to PLGA-COOH via acti-
vation of carboxylic acid by NHS and EDC according
to a described method [20, 21]: PLGA-COOH (3.6 g,
0.2 mmol) was converted to PLGA-NHS with excess
NHS (95 mg, 0.8 mmol) in EDC (150 mg, 0.8 mmol)
and methylene chloride (7.0 mL) while stirring over
for 24 h. Unreacted NHS and EDC were removed by
the use of a solution containing 70 % ethyl ether and
30 % methanol. After precipitation with ethyl ether,
PLGA-NHS was dissolved in chloroform, followed by
addition of NH2-PEG-OH (0.05 mmol) and N,N-diiso-
propylethylamine (Fisher Scientific) (0.2 mmol) and stirred
overnight. The resulting PLGA-PEG copolymers were
precipitated with cold methanol and dried under vacuum
for storage prior to further treatment.
Preparation of Antibody-Coated and Drug-Loaded
PLGA-PEG NPs
For scFv CD45RO antibody conjugation to PLGA-PEG,
the PLGA-PEG (10 mg) and antibody (2.5 mg) were
dissolved in 600 μL of 50/50 acetonitrile/DMF [22, 23]
and stirred overnight. The product was precipitated with
2 mL of an ice-cold 80/20 mix of diethyl ether/methanol,
centrifuged at 4500g for 15 min, and re-dissolved in
600 μL 50/50 acetonitrile/DMF. This cycle was repeated
three times, and the antibody-PLGA-PEG polymer was
dried under vacuum. Antibody-PLGA-PEG NPs, simul-
taneously loaded with SAHA and Nel, were prepared
via a single oil/water emulsion and evaporation method
[24, 25]. One hundred milligrams of antibody-PLGA-
PEG NPs, 25 mM of SAHA, and 25 mM of Nel were
dissolved in 1.5 ml of dichloromethane, which formed the
organic phase. The organic phase was emulsified with
4 ml of pH 7.4 phosphate-buffered saline containing PVA
205 (3 %, w/v) by probe sonication (VC 505, Vibra-Cell
Sonics, Newtown, CT, USA) at 45 W for 30 s in an ice
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bath. The organic suspension was stirred for 5 h at 25 °C
and evaporated completely under reduced pressure. The
NPs were then isolated by ultracentrifugation (25,000 rpm
for 10 min), washed with ddH2O, and lyophilized. NPs
containing only SAHA or Nel were prepared by the use of
the aforementioned oil/water emulsion method [24, 25].
Morphological evaluation, average size, and zeta potential
of the NPs were analyzed by the use of transmission elec-
tron microscope (TEM; JEOL JEM 1200 EXII) and a
dynamic light-scattering detector (DLS; Malvern Zetasizer
2000, Malvern, UK). In order to obtain fluorescing images,
NPs were loaded with 1 % (w/w) coumarin-6.
Measurement of Drug Loading, Entrapping, and Release
To determine the amount of drug loaded, single or dual
drug-loaded NPs (5.0 mg) were dissolved in 1.5 mL of
dimethylsulfoxide for 15 min by sonication. Then,
2.0 mL of methanol was added to precipitate the dipoly-
mer. After centrifugation at 1500g for 20 min, the drug
quantity in the supernatant was analyzed by high-
performance liquid chromatography (HPLC). The load-
ing content (LC) and entrapment efficiency (EE) of the
drug-loaded NPs were calculated by the following equa-
tions [26, 27]:
LC % ¼ weight of drug in the NPsð Þ= weight of the NPsð Þ
 100 %;
EE % ¼ weight of drug in the NPsð Þ= input weight of drugð Þ
 100 %
To measure drug release from NPs, single or dual
drug-loaded NPs were lyophilized, weighed, re-
suspended in PBS/0.1 % Tween-80 at pH 7.0, and incu-
bated in a vibrating water bath at 37 °C and 130 rpm. At
various times between 30 min and 10 days, samples were
taken out and centrifuged at 25,000 rpm for 15 min. An
aliquot of the supernatant was removed for quantifica-
tion; this volume was replaced with fresh PBS/0.1 %
Tween-80 at pH 7.0. Drug release was estimated with
HPLC. The cumulative release of drug was plotted
against time.
Cellular Uptake and Intracellular Localization of NPs
To quantitate uptake kinetics, coumarin-6 NPs were
prepared for observation with confocal microscopy. T
cells were seeded at 1 × 103 cells per well and incubated
with coumarin-6 NPs suspended in medium with 5 μM
rhodamine at 37 °C with 5 % CO2. At various time points
(from 30 min to 6 h), wells were treated with Hoechst
33342 nucleic acid stain (Invitrogen) for 15 min. The
medium was removed, and cells were washed three times
with PBS and fixed with methanol for 25 min. Confocal
fluorescence images were acquired with a Nikon Ti-E
microscope equipped with an UltraVIEW VoX confocal
attachment (Perkin Elmer).
Cytotoxicity Assays
The cytotoxicity of NPs was evaluated in ACH-2 cells by
the use of the Cell-Quant™ alamarBlue cell viability
reagent (GeneCopoeia, Rockville, MD, USA). Briefly,
cells were seeded in 96-well plates (Costar, Chicago, IL,
USA) at 5 × 102 viable cells/well in Dulbecco’s modified
Eagle’s medium (Invitrogen, USA) supplemented with
10 % heat-inactivated fetal bovine serum (HyClone,
USA) under 5 % CO2 at 37 °C and incubated for 24 h to
allow cell attachment. The medium was replaced with
150 μL of medium containing NPs at various concentra-
tions (0.1 to 32 mg/mL) and incubated for 48 h. Then,
20 μL of the alamarBlue cell viability reagent was added
to the culture medium for 4 h. Fluorescence was
measured at Ex/Em = 545/590 nm. For cell viability,
400 μL of cell suspension (1 × 104 cells/mL) was mixed
with 0.1 mL of 0.4 % trypan blue dye, after being incu-
bated at 25 °C for 2 min. The cell viability rate was
calculated as followed: cell viability (%) = (number viable
cells/number total cells) × 100 %.
Protein Extraction and Western Blot Analysis
Cells (2.0 × 106) with different treatments were collected
and centrifuged at 1500 rpm for 15 min at 4 °C and then
washed with PBS. Protein was extracted from cells of
different groups with Triton X100 lysis buffer (100 μl)
and quantified by the use of the BCA Protein Assay
(Pierce Biotechnology). Proteins were separated on
gradient SDS-PAGE gels and transferred to nitrocellu-
lose membranes. After blocking in 5 % (w/v) skim milk
at room temperature for 30 min, membranes were incu-
bated with the specific primary antibody overnight at 4 °C.
Following incubation with secondary antibody conjugated
to horseradish peroxidase for 1 h at room temperature,
the bands were analyzed with the enhanced chemilumin-
escence system (Pierce Biotechnology).
HIV p24 Protein Level
HIV-1 p24 antigen was quantified in drug-treated cell
culture supernatants by the use of a commercially avail-
able ELISA kit (p24 HIV antigen ELISA kit, Perkin
Elmer) according to the manufacturer’s protocol.
Quantification of HIV RNA Transcripts
Total RNA was extracted from ACH-2 cells or culture su-
pernatants by TRIzol. HIV RNA levels were measured by
RT-qPCR (Roche TaqMan 2.0). The following primer sets
were used for PCR amplification: histone deacetylase
4 (HDAC4) mRNA forward 5′-GGTTTATTCTGAT
TGAGAACTGG-3′ and reverse 5′-ATTGTAAACC
ACAGTGCTCGC-3′; HIV Gag mRNA forward 5′-
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GGTGCGAGAGCGTCAGTATTAAG-3′ and reverse 5′-
AGCTCCCTGCTTGCCCATA-3′; and GAPDH mR
NA forward 5′-CGGAGTCAACGGATTTGGTCGTAT-
3′ and reverse 5′-AGCCTTCTCCATGGTGGTGAAGA
C-3′.
Statistical Analysis
Results were expressed as mean ± standard error of
the mean (SEM). The statistical significance between
groups was determined using either unpaired or paired
tests. p values of <0.05 were considered statistically
significant.
Discussion
Characterization of the Antibody-PLGA-PEG Copolymer
Initial analysis of NP morphology by TEM (Fig. 1a)
revealed a spherical shape, a particle size of about
125 nm, and a narrow size distribution: an excellent
range for tumor penetration and retention [28]. Dynamic
light scattering analysis confirmed the TEM data on NP
size (Fig. 1b). Compared with Ab-SAHA and Ab-Nel
NPs, which have a ζ potential value of −16.5 and
−16.2 mV, respectively, the Ab-SAHA/Nel NPs exhibited
higher ζ potential values of around −14.6 mV. The size
variation of synthetic NPs had no significant effect on
the ζ potential values (Table 1). The negative surface
charge may be due to the presence of ionized carboxyl
groups on PLGA segments [29]. The antibody PLGA-
PEG copolymer was dissolved in DMSO and analyzed
with 1H-NMR spectroscopy. The 1H-NMR peaks were
as follows: the characteristic peak of the -CH2 (ethylene
glycol protons) was at 3.6 ppm and the peaks of the -CH
(lactide proton), -CH2 (glycolide proton), and -CH3
(lactide proton) were at 5.2, 4.8, and 1.7 ppm, respect-
ively (Fig. 1c). These 1H-NMR spectra confirmed peptide
coupling to PLGA-PEG copolymer as well as the
presence of both PLGA and PEG domains in the PLGA-
PEG synthetic copolymer.
Drug Release Profiles
Both SAHA and Nel encapsulated into NPs in a 1:1
molar ratio. As shown in Fig. 2, the non-Ab-
modified nanoparticles showed biphasic release char-
acteristics, i.e., an immediate release (“burst effect”)
Fig. 1 Characterization of nanoparticles. a TEM images of the representative antibody-PLGA-PEG NPs. The scale bar is 200 nm. b Diameter
Z-average of antibody-PLGA-PEG NPs. c A representative 1H-NMR spectrum of the antibody-PLGA-PEG copolymer
Table 1 Physicochemical characteristics of synthetic NP
formulations
Formulation Size (nm) PDI ZP (mV) EE (%)
Ab-SAHA NPs 119 ± 3.2 0.13 ± 0.005 −16.5 ± 1.7 80
Ab-Nel NPs 118 ± 2.3 0.14 ± 0.006 −16.2 ± 1.5 84
Ab-SAHA/Nel NPs 125 ± 1.9 0.17 ± 0.008 −14.6 ± 4.3 78a
80b




Tang et al. Nanoscale Research Letters  (2015) 10:413 Page 4 of 8
followed by a slower release profile. However, no ini-
tial burst release was observed for Ab-modified NPs.
The drugs (SAHA and Nel) were released from Ab-
modified nanoparticles in a sustained manner for up
to 180 h, providing a prolonged biological effect. On
this basis, these NPs were selected for further bio-
logical studies.
Ex Vivo Study of scFv CD45RO-Coumarin-6 NP Cellular
Uptake
In order to evaluate our NPs as delivery vehicles for tar-
get cells, we loaded them with the fluorescent dye
coumarin-6 and incubated them with H9 cells for 12 h,
and the uptake was evaluated by flow cytometry and
confocal laser scanning microscope (CLSM). As shown
Fig. 2 In vitro release profiles of SAHA and Nel from NPs incubated in phosphate-buffered saline (pH 7.0). The data are presented as
mean ± SEM (n = 3)
Fig. 3 Cellular uptake analysis of coumarin-6-labelled NPs. a Confocal images of H9 cells. Cells were treated with scFv CD45RO-coumarin-6 NPs or
coumarin-6 NPs and incubated for 12 h. Nuclei were stained with Hoechst 33342 (blue) and coumarin-6 (green) (×400). b Flow cytometry analysis
of cellular uptake of scFv CD45RO-coumarin-6 NPs in a time-dependent manner. Representative histogram overlay (white peaks, 0 h post incubation;
gray peaks, 12 h post incubation)
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in Fig. 3, scFv CD45RO-coumarin-6 NPs showed a defin-
ite cellular uptake within 12 h. In contrast, the
coumarin-6 NPs showed little uptake during the same
incubation period. The merged images show cytosolic
localization of scFv CD45RO-coumarin-6 NPs that is dis-
tinct from the nuclear Hoechst 33342 stain. These
results demonstrate the time-dependent cellular intern-
alization of scFv CD45RO-coumarin-6 NPs. It is likely
that the analogous NPs loaded with drugs will show a
similar trafficking pattern and release their cargo after
internalization, reducing the non-specific distribution
and increasing the intracellular concentrations of the
drugs. This effect would, in turn, enhance drug interac-
tions with HIV components and improve their thera-
peutic effects.
Cytotoxic Effects of NPs on ACH-2 Cells
To assess the cellular cytotoxicity of the NPs, ACH-2
cells were incubated with NPs (0.1 to 32 mg/mL) and
analyzed for cell viability. After 48 h of exposure to the
NPs, cell viability was assessed using the Cell-Quant™ ala-
marBlue cell viability reagent (GeneCopoeia, Rockville,
MD, USA). The results of three independent assays were
plotted onto a fitted curve to obtain median lethal dose
(LD50) values. The experimental LD50 values were
13.8 mg/mL for SAHA/Nel NPs and 16.0 mg/mL for scFv
CD45RO-SAHA/Nel NPs. The experimental LD50 for scFv
CD45RO-SAHA/Nel NPs corresponds to approximately
5–10 g/kg of body weight, which is much higher than the
intravenous dose required for in vivo drug delivery (Fig. 4).
These results suggest that the in vitro cytotoxicity of the
scFv CD45RO-SAHA/Nel NPs was low.
scFv CD45RO-SAHA/Nel NPs Activate Latent HIV in ACH-2
Cells
SAHA can induce hyperacetylation of the HIV
promoter-associated nucleosomes to activate latent HIV
by suppressing cellular HDAC expression and binding to
the HIV promoter [30–32]. We investigated the change
in HDAC4 expression in ACH-2 cells incubated with
scFv CD45RO-SAHA/Nel NPs and scFv CD45RO-SAHA
NPs. Our results showed a gradual reduction in HDAC4
mRNA and protein expression in cells treated with both
scFv CD45RO-SAHA/Nel NPs and scFv CD45RO-SAHA
NPs, reaching virtually undetectable levels after 24 h.
(Fig. 5a, b). At the same time, viral RNA levels progres-
sively increased, reaching about 40-fold higher levels
than the control after 48 h of incubation (Fig. 5c).
Therefore, scFv CD45RO-SAHA/Nel NPs stimulated
Fig. 4 Cytotoxicity of drug-loaded NPs in ACH-2 cells with the
Cell-Quant™ alamarBlue cell viability reagent assay. The data were
presented as mean ± SEM (n = 3)
Fig. 5 HDAC4 in ACH-2 cells treated with scFv CD45RO-SAHA NPs or scFv CD45RO-SAHA/Nel NPs was downregulated, leading to HIV-1 reactivation in
ACH-2 cells. a Real-time PCR quantification of HDAC4 mRNA expression and b immunoblotting of HDAC4 protein levels on whole-cell
lysates from ACH-2 cells cultivated in the presence scFv CD45RO-SAHA NPs, scFv CD45RO-SAHA/Nel NPs, or control (DMEM) at the
indicated times. c Real-time PCR quantification of HIV-1 RNA in ACH-2 cells treated with PBS (control), scFv CD45RO-SAHA NPs, or scFv
CD45RO-SAHA/Nel NPs for the indicated times. Results were expressed as the fold change vs. the control at each time point (mean ±
SEM of three independent experiments)
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HIV-1 mRNA expression and inhibited cellular HDAC4
expression.
scFv CD45RO-SAHA/Nel NPs Inhibit HIV Infection
In order to analyze the efficacy of the scFv CD45RO-
SAHA/Nel NPs to activate latent proviruses [33, 34],
ACH-2 cells were incubated in the presence of 2.0 mg/
mL scFv CD45RO-SAHA/Nel NPs, scFv CD45RO-SAHA
NPs, or control (DMEM) for 24 h at 37 °C. The condi-
tioned medium from these cells was then transferred to
untreated cells and incubated for 72 h. At this time, HIV
p24 could hardly be detected in the scFv CD45RO-
SAHA/Nel-NP-treated cells, while in scFv CD45RO-
SAHA-NP-treated cells, p24 levels were significantly
elevated relative to the control. These data confirmed
that scFv CD45RO-SAHA/Nel NPs could inhibit virus
spread in ACH-2 cells (Fig. 6). Conceptually, this finding
represents a safety feature whereby any virus induced by
the latency activator is also inactivated by the protease
inhibitor, thereby impeding virus spread. In this way, the
limited production of viable virus would facilitate subse-
quent targeting by the immune response. Hence, the
scFv CD45RO-SAHA/Nel NPs can effectively stimulate
latent virus and also inhibit virus spread, which further
exemplifies the potential benefits of using nanoparticles
in HIV purging strategies.
Conclusion
HIV-1 mainly targets human CD4
+ T cells that continue
to harbor latent proviruses after infection. Eradicating la-
tent HIV in Tm cellular reservoirs is the most important
barrier to curing AIDS [34]. SAHA is a potent HDAC
inhibitor capable of reactivating HIV-1 expression from
latently infected cells [9–11], and Nel is a potent
bioavailable HIV-1 protease inhibitor, which is widely
prescribed in combination with HIV reverse transcript-
ase inhibitors for the treatment of HIV infection. We
have developed NPs, conjugated to the Tm cell-specific
antibody scFv CD45RO, which are able to specifically
bind to Tm cells. When high concentrations of SAHA
were delivered from these particles, a stable increase in
viral reactivation without detectable cytotoxicity oc-
curred. Moreover, scFv CD45RO-conjugated NPs loaded
with both SAHA and Nel produced particles capable of
both activating latent virus and inhibiting viral spread.
Taken together, these data demonstrate the ability of
nanotechnology to improve conventional approaches for
activating latent HIV. This study provides a key proof-
of-principle experiment, which opens up avenues to
eradicate HIV infection by eliminating latent viral reser-
voirs via T-cell-specific delivery of an HDAC inhibitor in
combination with a protease inhibitor.
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